Polyrizon Ltd. Closes $4.0 Million Registered Direct Offering and Private Placement

Polyrizon Ltd. (NASDAQ: PLRZ), a development-stage biotech company specializing in intranasal hydrogels, announced the closing of a $4.0 million registered direct offering and concurrent private placement on September 4, 2026. The transaction involved a single institutional investor purchasing 333,333 units at a price of $12.00 per unit. These units consisted of ordinary shares (or pre-funded warrants) and common warrants. Specifically, the company issued 232,500 ordinary shares and 30,000 pre-funded warrants in the registered direct offering, along with 70,833 PIPE pre-funded warrants and 333,333 PIPE common warrants in the private placement. The common warrants carry an exercise price of $12.00 per share. Polyrizon intends to utilize the net proceeds, combined with existing cash reserves, for general corporate purposes and working capital. Aegis Capital Corp. served as the exclusive placement agent for the transaction. This funding supports the company's continued development of its proprietary Capture and Contain (C&C) and Trap and Target (T&T) hydrogel technologies.